ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending

Reuters

Nov 12, 2025

ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending

ProMIS Neurosciences Inc. reported financial results for the third quarter ended September 30, 2025. Research and development expenses increased to $9.8 million for the quarter, compared to $2.6 million in the same period of 2024. For the nine months ended September 30, 2025, research and development expenses were $24.0 million, up from $6.3 million in the prior year period. The accumulated deficit as of September 30, 2025, was $119.7 million, compared to $90.7 million as of September 30, 2024. Total shareholders' equity was $9.2 million, down from $16.5 million in the previous year. During the period, ProMIS focused on advancing its PRECISE-AD trial for its first clinical candidate, PMN310, and strengthened its board with the addition of Slanix Paul Alex, Pharm.D. The company also raised additional capital to support its strategic and clinical goals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582006373"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582006373\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582006373?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582006373","market":"nz","top_or_hot":-1,"title":"ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PMN\">ProMIS Neurosciences Inc</a>. reported financial results for the third quarter ended September 30, 2025. Research and development expenses increased to $9.8 million for the quarter, compared to $2.6 million in the same period of 2024. For the nine months ended September 30, 2025, research and development expenses were $24.0 million, up from $6.3 million in the prior year period. The accumulated deficit as of September 30, 2025, was $119.7 million, compared to $90.7 million as of September 30, 2024. Total shareholders' equity was $9.2 million, down from $16.5 million in the previous year. During the period, ProMIS focused on advancing its PRECISE-AD trial for its first clinical candidate, PMN310, and strengthened its board with the addition of Slanix Paul Alex, Pharm.D. The company also raised additional capital to support its strategic and clinical goals.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PMN\">ProMIS Neurosciences Inc</a>. reported financial results for the third quarter ended September 30, 2025. Research and development expenses increased to $9.8 million for the quarter, compared to $2.6 million in the same period of 2024. For the nine months ended September 30, 2025, research and development expenses were $24.0 million, up from $6.3 million in the prior year period. The accumulated deficit as of September 30, 2025, was $119.7 million, compared to $90.7 million as of September 30, 2024. Total shareholders' equity was $9.2 million, down from $16.5 million in the previous year. During the period, ProMIS focused on advancing its PRECISE-AD trial for its first clinical candidate, PMN310, and strengthened its board with the addition of Slanix Paul Alex, Pharm.D. The company also raised additional capital to support its strategic and clinical goals.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PMN","symbol_name":"ProMIS Neurosciences Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL4cqxzN:1","article_id":"2582006373","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582006373","pubTimestamp":1762949131,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ProMIS Neurosciences Inc. reported financial results for the third quarter ended September 30, 2025. Research and development expenses increased to $9.8 million for the quarter, compared to $2.6 million in the same period of 2024. For the nine months ended September 30, 2025, research and development expenses were $24.0 million, up from $6.3 million in the prior year period. The accumulated deficit as of September 30, 2025, was $119.7 million, compared to $90.7 million as of September 30, 2024. Total shareholders' equity was $9.2 million, down from $16.5 million in the previous year. During the period, ProMIS focused on advancing its PRECISE-AD trial for its first clinical candidate, PMN310, and strengthened its board with the addition of Slanix Paul Alex, Pharm.D. The company also raised additional capital to support its strategic and clinical goals.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PMN":"ProMIS Neurosciences Inc","BK4139":"生物科技"},"translate_title":"ProMIS Neurosciences因临床试验支出增加而第三季度亏损1180万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PMN":0.9},"content_text":"ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending\n    \n\nProMIS Neurosciences Inc. reported financial results for the third quarter ended September 30, 2025. Research and development expenses increased to $9.8 million for the quarter, compared to $2.6 million in the same period of 2024. For the nine months ended September 30, 2025, research and development expenses were $24.0 million, up from $6.3 million in the prior year period. The accumulated deficit as of September 30, 2025, was $119.7 million, compared to $90.7 million as of September 30, 2024. Total shareholders' equity was $9.2 million, down from $16.5 million in the previous year. During the period, ProMIS focused on advancing its PRECISE-AD trial for its first clinical candidate, PMN310, and strengthened its board with the addition of Slanix Paul Alex, Pharm.D. The company also raised additional capital to support its strategic and clinical goals.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}